n Cardiovascular Journal of South Africa - Lovastatin - candidate for non-prescription availability in US market : drug trends in cardiology

Volume 16, Issue 3
  • ISSN : 1680-0745



Extracted from text ... A recent review of two decades of use of lovastatin in the United States has highlighted the extremely low risk of myopathy1 and rhabdomyolysis associated with the use of this statin. Myopathy is a reversible, adverse drug reaction associated with all statins and defined as a serum creatine kinase (CK) level more than 10 times the upper limit of normal (ULN), with muscle symptoms. Rhabdomyolysis is the most severe form of myopathy, recently defined as muscle symptoms with marked CK elevation (typically substantially more than 10 times the ULN). The risk for lovastatin-associated muscle disease is best evaluated by data from ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error